RESUMEN
Glans penis morphology has been used as a powerful tool in mammal taxonomy to differentiate cryptic species. Neotropical rodent species Akodoncursor and A.montensis are cryptic, and interspecific hybrids are like their parental species. We investigated non-metric and metric phallic characters aiming to differentiate A.cursor from A.montensis. We also evaluated the parental species' influence of the phallic characters on hybrids. We analysed 96 male adults-56 A.cursor, 27 A.montensis, and 13 hybrids, subgrouping species by locality and hybrids by parental species (paternal vs maternal). We verified that A.cursor and A.montensis are distinguishable by penile-shape morphology: A.cursor has an elongated penile form with a flare in the distal portion and A.montensis has a barrel-shaped form. Also, dark spots in ventral view, if present in A.montensis, distinguish A.montensis from A.cursor. Although the non-metric characters differentiate the species, they do not distinguish the subgroups of A.cursor, A.montensis, and hybrids. The metric phallic characters indicated a significant difference between species and hybrids. These characters also differentiate the population groups of A.cursor. However, A.montensis subgroups and hybrids subgroups did not present a significant difference. This study shows the importance of penis morphology in the taxonomy of the cryptic rodent species A.cursor and A.montensis, representing a powerful tool to discriminate male specimens in mammal collections without karyotyping or sequencing, even though the specimens occurred in sympatric areas. Since most taxidermy protocols do not preserve the penis in mammal preparations, liquid preservation of some specimens or the removal of the penis before taxidermy for liquid preservation could be beneficial. We also recommend the organisation in museum collections of a penis bank for the A.cursor species group (or even all rodent species) to avoid losing this important information for species identification.
RESUMEN
Introducción: El CIGB-258 es un péptido inmunomodulador con propiedades antiinflamatorias. Objetivos: Establecer la frecuencia de dosis y el tiempo de tratamiento con el péptido CIGB-258, para pacientes críticos con COVID-19. Además, definir los criterios de uso y el esquema terapéutico del péptido, para pacientes graves con COVID-19. Métodos: Se incluyeron 9 pacientes críticos y 3 pacientes graves. Las evaluaciones clínicas, radiológicas y de laboratorio se registraron de acuerdo al protocolo establecido. Se obtuvieron muestras de suero antes y después del tratamiento con la CIGB-258, para la determinación de los biomarcadores de la inflamación. Resultados: Se estableció el protocolo de actuación con el péptido CIGB-258, el cual consiste en la administración intravenosa de 1 mg del péptido cada 12 horas a los pacientes críticos. La dosis debe aumentarse a 2 mg cada 12 horas, para los pacientes que no muestren mejoría clínica y radiológica en 24 horas. Después de la extubación, los pacientes deben recibir 1 mg de CIGB-258 al día, durante otros tres días. Los pacientes graves deben recibir 1 mg de CIGB-258 cada 12 horas, hasta que resuelvan su condición clínica. Conclusiones: CIGB-258 mostró un buen perfil de seguridad. El protocolo de actuación establecido contribuyó a que todos los pacientes críticos se recuperaran de la dificultad respiratoria y fueran extubados. Los pacientes graves mejoraron considerablemente. Los niveles de los biomarcadores asociados con hiperinflamación y las citocinas disminuyeron significativamente durante el tratamiento(AU)
Introduction: CIGB-258 is an immunomodulatory peptide with anti-inflammatory properties. Objectives: To establish the therapeutic schedule with CIGB-258 peptide for COVID-19 critically ill patients. In addition, to define the criteria for use and schedule of this peptide for COVID-19 seriously ill patients. Methods: 9 critically ill patients and 3 seriously ill patients were included in this study. Clinical, radiological and laboratory evaluations were recorded according to the established protocol. Serum samples were obtained before and after treatment with CIGB-258, for the determination of the inflammation biomarkers. Results: The therapeutic protocol was established with the CIGB-258 peptide, which consists of intravenous administration of 1 mg of peptide every 12 hours for critically ill patients. The dose should be increased to 2 mg every 12 hours, for patients who do not show clinical and radiological improvement in 24 hours. After extubation, patients should receive 1 mg of CIGB-258 daily, for another three days. Seriously ill patients should receive 1 mg of CIGB-258 every 12 hours, until their clinical condition resolves. Conclusions: CIGB-258 showed an excellent safety profile. The established therapeutic protocol contributed to all critically ill patients recovering from respiratory distress and being extubated. Seriously ill patients improved considerably. The levels of the biomarkers associated with hyperinflammation and cytokines decreased significantly during treatment(AU)
